Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
ASTRIS
Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy With an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)
1 other identifier
interventional
3,017
15 countries
197
Brief Summary
The aim of this study is to assess the efficacy and safety of single agent AZD9291 in a real world setting in adult patients with advanced or metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive Non-Small Cell Lung Cancer (NSCLC), who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 lung-cancer
Started Sep 2015
197 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 27, 2015
CompletedFirst Posted
Study publicly available on registry
June 17, 2015
CompletedStudy Start
First participant enrolled
September 18, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 18, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
April 18, 2019
CompletedResults Posted
Study results publicly available
October 25, 2021
CompletedNovember 11, 2021
November 1, 2021
3.6 years
May 27, 2015
August 12, 2021
November 10, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Overall Survival (OS)
OS was defined as the time, in months from the date of first dose of Osimertinib until death due to any cause, or at last documented contact with participant status "alive" (in this study any participants alive at study discontinuation, or lost to follow-up was considered being censored at study discontinuation date or at the last known date participant was alive). OS was summarized using a Kaplan-Meier (KM) estimate of the median time to death or censoring together with their 95% confidence intervals.
From the date of first dose of Osimertinib until the date of death (due to any cause) or last participant contact [up to 43 months]
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Safety assessment of Osimertinib was analyzed by evaluating AEs and SAEs.
From screening to progression follow-up [every 6 weeks +/- 1 week] relative to the date of enrolment until the end of study [up to 43 months]
Secondary Outcomes (3)
Progression Free Survival
From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]
Time to Treatment Discontinuation (TTD)
From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]
Response Rate (RR)
From the date of first dose of Osimertinib until disease progression or death in the absence of progression [up to 43 months]
Study Arms (1)
AZD9291
EXPERIMENTALSingle arm of AZD9291, starting dose of 80mg
Interventions
If a previous lab report is unavailable, the patient will need to have T790M+ testing.
Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
Eligibility Criteria
You may qualify if:
- Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific procedures
- Adults (according to each country regulations for age of majority)
- Locally advanced (stage IIIB) or metastatic (stage IV) EGFRm NSCLC, not amenable to curative surgery or radiotherapy, with confirmation of the presence of the T790M mutation
- Prior therapy with an EGFR-TKI. Patients may have also received additional lines of treatment
- World Health Organization (WHO) performance status 0-2
- Adequate bone marrow reserve and organ function as demonstrated by complete blood count, biochemistry in blood and urine at baseline (please refer to IB for guidance)
- Female patients of childbearing potential must be using adequate contraceptive measures, must not be breast feeding, and must have a negative pregnancy test prior to start of dosing. Otherwise, they must have evidence of nonchildbearing potential
- Male patients must be willing to use barrier contraception, i.e., condoms
You may not qualify if:
- Previous (within 6 months) or current treatment with AZD9291
- Patients currently receiving (or unable to stop use at least 1 week prior to receiving the first dose of AZD9291) any treatment known to be potent inhibitors or inducers of cytochrome P450 (CYP) 3A4
- Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, active infection including hepatitis B, hepatitis C, and human immunodeficiency virus, or significantly impaired bone marrow reserve or organ function, including hepatic and renal impairment, which in the investigator's opinion would significantly alter the risk/benefit balance.
- Patient with symptomatic central nervous system (CNS) metastases who is neurologically unstable or has required increasing doses of steroids to manage CNS symptoms within the 2 weeks prior to start AZD9291 administration;
- Past medical history of ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
- Any of the following cardiac criteria:
- Mean resting corrected QT interval (QTcF) \> 470 ms using Fredericia's formula :
- Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block)
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
- Any unresolved toxicity from prior therapy CTCAE \> grade 3 at the time of starting treatment
- History of hypersensitivity to excipients of AZD9291 or to drugs with a similar chemical structure or class to AZD9291
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
- Parexelcollaborator
Study Sites (201)
Research Site
Buenos Aires, C1025ABI, Argentina
Research Site
Buenos Aires, C1431FWO, Argentina
Research Site
CABA, C1426ANZ, Argentina
Research Site
Bedford Park, 5042, Australia
Research Site
East Melbourne, 3002, Australia
Research Site
Kurralta Park, 5037, Australia
Research Site
Randwick, 2031, Australia
Research Site
Waratah, 2298, Australia
Research Site
Innsbruck, 6020, Austria
Research Site
Linz, 4020, Austria
Research Site
Salzburg, 5020, Austria
Research Site
Vienna, 1140, Austria
Research Site
Charleroi, 6000, Belgium
Research Site
Edegem, 2650, Belgium
Research Site
Leuven, 3000, Belgium
Research Site
Barretos, 14784-400, Brazil
Research Site
Belo Horizonte, 30380-472, Brazil
Research Site
Florianópolis, 88034-000, Brazil
Research Site
Ijuí, 98700-000, Brazil
Research Site
Itajaí, 88310-110, Brazil
Research Site
Porto Alegre, 90035-903, Brazil
Research Site
Porto Alegre, 90610-000, Brazil
Research Site
Rio de Janeiro, 20231-050, Brazil
Research Site
Rio de Janeiro, 22793-080, Brazil
Research Site
Salvador, 40170-110, Brazil
Research Site
Salvador, 41950-640, Brazil
Research Site
São Paulo, 01221-020, Brazil
Research Site
São Paulo, 01246-000, Brazil
Research Site
São Paulo, 01509-900, Brazil
Research Site
Calgary, Alberta, T2N 4N2, Canada
Research Site
Burnaby, British Columbia, V5G 2X6, Canada
Research Site
Vancouver, British Columbia, V5Z 4E6, Canada
Research Site
Hamilton, Ontario, L8V 5C2, Canada
Research Site
North York, Ontario, M2K 1E1, Canada
Research Site
Oshawa, Ontario, L1G 2B9, Canada
Research Site
Toronto, Ontario, M4N 3M5, Canada
Research Site
Toronto, Ontario, M5G 1X5, Canada
Research Site
Toronto, Ontario, M5G 2M9, Canada
Research Site
Montreal, Quebec, H4A 3J1, Canada
Research Site
Québec, Quebec, G1V 4G5, Canada
Research Site
Regina, Saskatchewan, S4T 7T1, Canada
Research Site
Beijing, 100020, China
Research Site
Beijing, 100021, China
Research Site
Beijing, 100044, China
Research Site
Beijing, 100048, China
Research Site
Beijing, 100053, China
Research Site
Beijing, 100071, China
Research Site
Beijing, 100142, China
Research Site
Beijing, 100730, China
Research Site
Beijing, 100853, China
Research Site
Beijing, 101149, China
Research Site
Changchun, 130012, China
Research Site
Changchun, 130021, China
Research Site
Changsha, 410003, China
Research Site
Chengdu, 610041, China
Research Site
Chongqing, 400037, China
Research Site
Chongqing, 400038, China
Research Site
Chongqing, 400042, China
Research Site
Dalian, 116011, China
Research Site
Fuzhou, 350009, China
Research Site
Fuzhou, 350014, China
Research Site
Fuzhou, 350025, China
Research Site
Guangzhou, 510080, China
Research Site
Guangzhou, 510120, China
Research Site
Guangzhou, 510515, China
Research Site
Haikou, 570311, China
Research Site
Hangzhou, 310003, China
Research Site
Hangzhou, 310006, China
Research Site
Hangzhou, 310009, China
Research Site
Hangzhou, 310022, China
Research Site
Harbin, 150049, China
Research Site
Hefei, 230001, China
Research Site
Hohhot, 010017, China
Research Site
Jinan, 2501117, China
Research Site
Kunming, 650118, China
Research Site
Linhai, 317000, China
Research Site
Nanchang, 330006, China
Research Site
Nanjing, 210002, China
Research Site
Nanjing, 210006, China
Research Site
Nanjing, 210008, China
Research Site
Nanjing, 210009, China
Research Site
Nanjing, 210029, China
Research Site
Nanning, 530021, China
Research Site
Nantong, 226361, China
Research Site
Qingdao, 266071, China
Research Site
Shanghai, 200025, China
Research Site
Shanghai, 200030, China
Research Site
Shanghai, 200032, China
Research Site
Shanghai, 200433, China
Research Site
Shenyang, 110001, China
Research Site
Shenyang, 110016, China
Research Site
Shenzhen, 518020, China
Research Site
Shijiahzhuang, 050011, China
Research Site
Tianjin, 300060, China
Research Site
Ürümqi, 830000, China
Research Site
Ürümqi, 830054, China
Research Site
Ürümqi, 831118, China
Research Site
Wuhan, 430022, China
Research Site
Wuhan, 430030, China
Research Site
Wuhan, 430071, China
Research Site
Wuhan, 430079, China
Research Site
Wuxi, 214062, China
Research Site
Xi'an, 710032, China
Research Site
Xi'an, 710061, China
Research Site
Yancheng, 224005, China
Research Site
Yangzhou, 225001, China
Research Site
Yantai, 264000, China
Research Site
Zhengzhou, 450008, China
Research Site
Vejle, 7100, Denmark
Research Site
Dublin, DUBLIN 4, Ireland
Research Site
Ancona, 60010, Italy
Research Site
Avellino, 83100, Italy
Research Site
Bari, 70124, Italy
Research Site
Bologna, 40138, Italy
Research Site
Brescia, 25100, Italy
Research Site
Cagliari, 09121, Italy
Research Site
Catania, 95123, Italy
Research Site
Florence, 50141, Italy
Research Site
Genova, 16132, Italy
Research Site
Lecce, 73100, Italy
Research Site
Livorno, 57124, Italy
Research Site
Milan, 20141, Italy
Research Site
Napoli, 80131, Italy
Research Site
Novara, 28100, Italy
Research Site
Palermo, 90146, Italy
Research Site
Parma, 43126, Italy
Research Site
Perugia, 06132, Italy
Research Site
Pisa, 56124, Italy
Research Site
Reggio Emilia, 42100, Italy
Research Site
Roma, 00144, Italy
Research Site
Roma, 00152, Italy
Research Site
Roma, 00189, Italy
Research Site
Udine, 33100, Italy
Research Site
Verona, 37126, Italy
Research Site
Dammam, 31444, Saudi Arabia
Research Site
Riyadh, 11426, Saudi Arabia
Research Site
Anyang, 14068, South Korea
Research Site
Busan, 47392, South Korea
Research Site
Busan, 49241, South Korea
Research Site
Busan, 49267, South Korea
Research Site
Cheongju-si, 28644, South Korea
Research Site
Daegu, 41944, South Korea
Research Site
Daegu, 42415, South Korea
Research Site
Daejeon, 35015, South Korea
Research Site
Gangneung-si, 25440, South Korea
Research Site
Goyang-si, 10408, South Korea
Research Site
Incheon, 21565, South Korea
Research Site
Jeonju, 54907, South Korea
Research Site
Jeonnam, 58128, South Korea
Research Site
JinJoo, 52727, South Korea
Research Site
Seogu, 49201, South Korea
Research Site
Seongnam-si, 13620, South Korea
Research Site
Seoul, 01812, South Korea
Research Site
Seoul, 03080, South Korea
Research Site
Seoul, 03181, South Korea
Research Site
Seoul, 03722, South Korea
Research Site
Seoul, 05030, South Korea
Research Site
Seoul, 05355, South Korea
Research Site
Seoul, 05368, South Korea
Research Site
Seoul, 05505, South Korea
Research Site
Seoul, 06351, South Korea
Research Site
Seoul, 06591, South Korea
Research Site
Seoul, 07345, South Korea
Research Site
Seoul, 08308, South Korea
Research Site
Seoul, 156-707, South Korea
Research Site
Suwon, 16499, South Korea
Research Site
Ulsan, 44033, South Korea
Research Site
A Coruña, 15006, Spain
Research Site
Alicante, 03010, Spain
Research Site
Badalona, 08916, Spain
Research Site
Barcelona, 08036, Spain
Research Site
Castellon, 12002, Spain
Research Site
Donostia / San Sebastian, 20014, Spain
Research Site
Jaén, 23007, Spain
Research Site
Las Palmas de Gran Canaria, 35016, Spain
Research Site
León, 24071, Spain
Research Site
Madrid, 28007, Spain
Research Site
Madrid, 28040, Spain
Research Site
Majadahonda, 28222, Spain
Research Site
Oviedo, 33011, Spain
Research Site
Palma de Mallorca, 07010, Spain
Research Site
Seville, 41071, Spain
Research Site
Valencia, 46010, Spain
Research Site
Valencia, 46026, Spain
Research Site
Zaragoza, 50009, Spain
Research Site
Örebro, 70185, Sweden
Research Site
Uppsala, 751 85, Sweden
Research Site
Kaohsiung City, 807, Taiwan
Research Site
Kaohsiung City, 833, Taiwan
Research Site
Taichung, 00407, Taiwan
Research Site
Tainan, 704, Taiwan
Research Site
Taipei, 10002, Taiwan
Research Site
Taipei, 11217, Taiwan
Research Site
Taipei, 11259, Taiwan
Research Site
Taoyuan District, 333, Taiwan
Research Site
Antrim, BT41 2RL, United Kingdom
Research Site
London, NW3 2QG, United Kingdom
Research Site
London, SW17 0QT, United Kingdom
Research Site
Norwich, NR4 7TY, United Kingdom
Research Site
Poole, BH15 2JB, United Kingdom
Research Site
Wolverhampton, WV10 0QP, United Kingdom
Related Publications (3)
Zhou Q, Zhang HL, Jiang LY, Shi YK, Chen Y, Yu JM, Zhou CC, He Y, Hu YP, Liang ZA, Pan YY, Zhuo WL, Song Y, Wu G, Chen GY, Lu Y, Zhang CY, Zhang YP, Cheng Y, Lu S, Wang CL, Zhou JY, Liu YP, He JX, Wang J, Wu YL. Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study. J Cancer Res Clin Oncol. 2023 Sep;149(12):10771-10780. doi: 10.1007/s00432-023-04923-8. Epub 2023 Jun 14.
PMID: 37316692DERIVEDCheema P, Cho BC, Freitas H, Provencio M, Chen YM, Kim SW, Wu YL, Passaro A, Martin C, Tiseo M, Chang GC, Park K, Solomon B, Burghuber O, Laskin J, Wang Z, Lee SY, Hu Y, Vansteenkiste J, Zhang HL, Hanrahan E, Geldart T, Taylor R, Servidio L, Li J, Marinis F. A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data. Future Oncol. 2023 Jan;19(1):61-75. doi: 10.2217/fon-2022-0919. Epub 2023 Jan 19.
PMID: 36656302DERIVEDLeighl NB, Kamel-Reid S, Cheema PK, Laskin J, Karsan A, Zhang T, Stockley T, Barnes TA, Tudor RA, Liu G, Owen S, Rothenstein J, Burkes RL, Iqbal M, Spatz A, van Kempen LC, Izevbaye I, Laurence D, Le LW, Tsao MS. Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. JCO Precis Oncol. 2020 Nov;4:520-533. doi: 10.1200/PO.19.00335.
PMID: 35050743DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
Participants alive at the time of national reimbursement or site closure were no longer followed for survival and therefore prematurely censored for the OS, PFS, and TTD analysis, leading to less mature data. As the timing of reimbursement and study closure differed between countries, duration of follow-up between sites and countries differed.
Results Point of Contact
- Title
- Global Clinical Lead
- Organization
- AstraZeneca Clinical study Information Center
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 27, 2015
First Posted
June 17, 2015
Study Start
September 18, 2015
Primary Completion
April 18, 2019
Study Completion
April 18, 2019
Last Updated
November 11, 2021
Results First Posted
October 25, 2021
Record last verified: 2021-11